Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a studyLindsey R. Baden, Hong‐Van Tieu, Guido Ferrari et al.|The Lancet HIV|2020Cited by 91
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humansWilton B. Williams, Barton F. Haynes, S. Munir Alam et al.|Cell|2024Cited by 50
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trialK. Rachael Parks, M. Juliana McElrath, Zoe Moodie et al.|Science Translational Medicine|2025Cited by 40
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a StudyDaniel J Stieh, Varun K. Phadke, Dan H. Barouch et al.|The Journal of Infectious Diseases|2022Cited by 36